Email Updates

You are here

An Advocates' Primer on Long-Acting Injectable Cabotegravir for PrEP


July 2020

In May and July 2020, the world learned new data from HPTN 083, a study of long-acting injectable cabotegravir (CAB-LA) for HIV prevention. This report summarizes the findings, unanswered questions and next steps for the development and introduction of CAB-LA.

Web-friendly version also available.